Sign In
Buy ENTX
$1.22
-0.0300 (-2.40%)
At Close: Jun 03, 2026
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts acr
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
04:05pm, Friday, 08'th May 2026
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitte
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 29'th Apr 2026
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
01:21pm, Monday, 20'th Apr 2026
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
11:59am, Monday, 20'th Apr 2026
In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
08:45am, Tuesday, 14'th Apr 2026
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
01:50pm, Monday, 06'th Apr 2026
MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
08:45am, Thursday, 02'nd Apr 2026
TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has enter
Editor's Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchm
U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% bel
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
04:05pm, Friday, 27'th Mar 2026
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comm
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
08:30am, Wednesday, 04'th Mar 2026
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours
01:49am, Thursday, 19'th Feb 2026
Entera Bio Ltd. shares jumped 15.71% in after-hours trading following a director's purchase of additional shares.
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
09:00am, Wednesday, 11'th Feb 2026
TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
08:50am, Monday, 09'th Feb 2026
New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant
